EG23757A - Benzoylguanidine derivatives with advantageous properties, processes for preparing them and their use in the production of pharmceutical compositions - Google Patents
Benzoylguanidine derivatives with advantageous properties, processes for preparing them and their use in the production of pharmceutical compositionsInfo
- Publication number
- EG23757A EG23757A EG118099A EG118099A EG23757A EG 23757 A EG23757 A EG 23757A EG 118099 A EG118099 A EG 118099A EG 118099 A EG118099 A EG 118099A EG 23757 A EG23757 A EG 23757A
- Authority
- EG
- Egypt
- Prior art keywords
- preparing
- processes
- production
- advantageous properties
- benzoylguanidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843489A DE19843489B4 (en) | 1998-09-22 | 1998-09-22 | Benzoylguanidine derivatives having advantageous properties, processes for their preparation and their use in the preparation of medicaments, and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EG23757A true EG23757A (en) | 2007-08-08 |
Family
ID=7881872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EG118099A EG23757A (en) | 1998-09-22 | 1999-09-22 | Benzoylguanidine derivatives with advantageous properties, processes for preparing them and their use in the production of pharmceutical compositions |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1165534B1 (en) |
| JP (1) | JP3817425B2 (en) |
| KR (1) | KR100621821B1 (en) |
| CN (1) | CN1166654C (en) |
| AR (1) | AR023668A1 (en) |
| AT (1) | ATE288425T1 (en) |
| AU (1) | AU764819C (en) |
| BG (1) | BG64985B1 (en) |
| BR (1) | BR9913107A (en) |
| CA (1) | CA2345006C (en) |
| CO (1) | CO5150207A1 (en) |
| CZ (1) | CZ300158B6 (en) |
| DE (2) | DE19843489B4 (en) |
| EA (1) | EA004687B1 (en) |
| EE (1) | EE04749B1 (en) |
| EG (1) | EG23757A (en) |
| ES (1) | ES2237951T3 (en) |
| HK (1) | HK1043367B (en) |
| HR (1) | HRP20010194B1 (en) |
| HU (1) | HU228955B1 (en) |
| ID (1) | ID27759A (en) |
| IL (1) | IL141805A (en) |
| MY (1) | MY121362A (en) |
| NO (1) | NO317993B1 (en) |
| NZ (1) | NZ511167A (en) |
| PE (1) | PE20001085A1 (en) |
| PL (1) | PL195291B1 (en) |
| PT (1) | PT1165534E (en) |
| RS (1) | RS49971B (en) |
| SA (1) | SA99200474B1 (en) |
| SK (1) | SK285578B6 (en) |
| TR (1) | TR200100801T2 (en) |
| TW (1) | TWI221841B (en) |
| WO (1) | WO2000017176A2 (en) |
| ZA (1) | ZA200101212B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10106970A1 (en) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharma | New benzoylguanidine salt |
| US6730678B2 (en) * | 2001-02-15 | 2004-05-04 | Boehringer Ingelheim Pharma Kg | Benzoylguanidine salt and hydrates thereof |
| DE10144030A1 (en) * | 2001-09-07 | 2003-03-27 | Boehringer Ingelheim Pharma | Composition containing 4-piperazino-benzoylguanidine derivative, useful e.g. for treating cardiac infarction, containing component to improve local tolerance, e.g. beta-cyclodextrin derivative or polymer |
| US6982256B2 (en) | 2001-09-07 | 2006-01-03 | Boehringer Ingelheim Pharma Kg | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration |
| FR2871157A1 (en) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | BIARYL AROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
| JP2011527677A (en) * | 2008-07-08 | 2011-11-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrrolidinyl and piperidinyl compounds useful as NHE-1 inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19601303A1 (en) * | 1996-01-16 | 1997-07-17 | Boehringer Ingelheim Kg | Novel benzoylguanidine derivatives, process for their preparation and their use in the manufacture of medicaments |
-
1998
- 1998-09-22 DE DE19843489A patent/DE19843489B4/en not_active Expired - Fee Related
-
1999
- 1999-08-17 SA SA99200474A patent/SA99200474B1/en unknown
- 1999-09-16 HU HU0200225A patent/HU228955B1/en not_active IP Right Cessation
- 1999-09-16 ES ES99952453T patent/ES2237951T3/en not_active Expired - Lifetime
- 1999-09-16 KR KR1020017003627A patent/KR100621821B1/en not_active IP Right Cessation
- 1999-09-16 DE DE59911568T patent/DE59911568D1/en not_active Expired - Lifetime
- 1999-09-16 JP JP2000574086A patent/JP3817425B2/en not_active Expired - Fee Related
- 1999-09-16 SK SK396-2001A patent/SK285578B6/en not_active IP Right Cessation
- 1999-09-16 WO PCT/EP1999/006857 patent/WO2000017176A2/en active IP Right Grant
- 1999-09-16 EA EA200100317A patent/EA004687B1/en not_active IP Right Cessation
- 1999-09-16 AU AU64659/99A patent/AU764819C/en not_active Ceased
- 1999-09-16 PT PT99952453T patent/PT1165534E/en unknown
- 1999-09-16 TR TR2001/00801T patent/TR200100801T2/en unknown
- 1999-09-16 NZ NZ511167A patent/NZ511167A/en not_active IP Right Cessation
- 1999-09-16 ID IDW20010663A patent/ID27759A/en unknown
- 1999-09-16 EP EP99952453A patent/EP1165534B1/en not_active Expired - Lifetime
- 1999-09-16 PL PL99347234A patent/PL195291B1/en unknown
- 1999-09-16 CN CNB998111430A patent/CN1166654C/en not_active Expired - Fee Related
- 1999-09-16 IL IL14180599A patent/IL141805A/en not_active IP Right Cessation
- 1999-09-16 CZ CZ20011047A patent/CZ300158B6/en not_active IP Right Cessation
- 1999-09-16 BR BR9913107-2A patent/BR9913107A/en not_active IP Right Cessation
- 1999-09-16 EE EEP200100178A patent/EE04749B1/en not_active IP Right Cessation
- 1999-09-16 RS YUP-215/01A patent/RS49971B/en unknown
- 1999-09-16 CA CA002345006A patent/CA2345006C/en not_active Expired - Fee Related
- 1999-09-16 AT AT99952453T patent/ATE288425T1/en active
- 1999-09-20 MY MYPI99004064A patent/MY121362A/en unknown
- 1999-09-20 PE PE1999000949A patent/PE20001085A1/en not_active Application Discontinuation
- 1999-09-21 CO CO99059852A patent/CO5150207A1/en unknown
- 1999-09-22 AR ARP990104775A patent/AR023668A1/en not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 1999-09-22 EG EG118099A patent/EG23757A/en active
- 1999-09-22 TW TW088116279A patent/TWI221841B/en not_active IP Right Cessation
-
2001
- 2001-02-13 ZA ZA200101212A patent/ZA200101212B/en unknown
- 2001-03-09 BG BG105326A patent/BG64985B1/en active Active
- 2001-03-15 HR HR20010194A patent/HRP20010194B1/en not_active IP Right Cessation
- 2001-03-21 NO NO20011428A patent/NO317993B1/en not_active IP Right Cessation
-
2002
- 2002-07-08 HK HK02105065.7A patent/HK1043367B/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL347500A1 (en) | Substituted 2-phenylbenzimidazoles, the production thereof and their use | |
| AU4504699A (en) | Metallocene-catalyzed oligodecenes, their production and their use as component in lubricants | |
| HUP0104200A3 (en) | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | |
| HUP0104917A3 (en) | Azepinoindole derivatives, the production and use thereof | |
| HUP0201225A3 (en) | 4,5,6,7-tetrahydroindazole derivatives as antitumor agent and process for their preparation | |
| IL142096A0 (en) | Indeno-, naphtho-and benzocyclohepta dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments | |
| PL320414A1 (en) | Novel derivatives of xantie, method of obtaining them, pharmaceutic agent, application of such derivatives in production of the pharmaceutic agent and method of obtaining same | |
| IL138702A0 (en) | Substituted indolinones, the production thereof and their use as medicaments | |
| HUP0004020A3 (en) | Tricyclic triazolobenzazepine derivatives, process for producing the same, and their use as antiallergic agent | |
| PL344255A1 (en) | Novel 1,5 and 3-o-substituted 1h-indazoles with anti-asthmatic, anti-allergic, anti-inflammatory, immuno-modulating and neuro-protective effect, method for the production and use thereof as medicaments | |
| IL139358A0 (en) | Novel 1,2,5-trisubstituted 1,2-dihydro-indazol-3-ones with anti-asthmatic, anti-allergic, anti-inflammatory, immuno-modulating and neuro-protective effect, method for the production and use thereof as medicaments | |
| EG23757A (en) | Benzoylguanidine derivatives with advantageous properties, processes for preparing them and their use in the production of pharmceutical compositions | |
| HU9801548D0 (en) | Blowing agent powder and process for producing the same | |
| HUP0202842A3 (en) | Spherical telithromycin clusters, method for their production and use thereof in the pharmaceutical compositions | |
| HUP0002491A3 (en) | Polymer composition, process for producing thereof and its use | |
| AU2940400A (en) | Cold-storage material with excellent shape stability and process for producing the same | |
| HK1043385A1 (en) | Beverages with ecological-biological properties and process for the preparation thereof | |
| GB2338712B (en) | Anti-fouling compositions, and their use in the polymerisation processes | |
| ZA986156B (en) | Blowing agent powder and process for producing the same | |
| HUP0104267A3 (en) | 1,4-diaryl-2-fluoro-1-buten-3-ol compounds and their use in the preparation of 1,4-diaryl-2-fluoro-1,3-butadiane and 1,4-diaryl-2-fluoro-2-butene compounds | |
| SI1127052T1 (en) | Substituted 2-phenylbenzimidazoles, the production thereof and their use |